South Dakota Investment Council Buys New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

South Dakota Investment Council bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 15,300 shares of the company’s stock, valued at approximately $370,000.

Other large investors have also recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Venturi Wealth Management LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $48,000. GAMMA Investing LLC grew its holdings in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the period. Finally, Principal Securities Inc. increased its position in Hims & Hers Health by 48.2% during the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after buying an additional 1,002 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Up 4.2 %

NYSE HIMS opened at $51.37 on Tuesday. The company has a market cap of $11.22 billion, a price-to-earnings ratio of 116.75 and a beta of 1.35. Hims & Hers Health, Inc. has a 1-year low of $9.67 and a 1-year high of $72.98. The company has a 50 day moving average of $35.45 and a 200-day moving average of $26.08.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent analyst reports. BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Piper Sandler raised their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Bank of America increased their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research report on Thursday, February 20th. Finally, Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.53.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 33,513 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. This represents a 50.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,080,275 shares of company stock valued at $37,247,354 over the last quarter. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.